11.1. Introduction {#s0010}
==================

The previous chapters have described the detection of different biomarkers for different diseases. Each chapter analyzed the different biomarker for a particular disease. In this chapter we analyze the binding and dissociation (if applicable) kinetics of other biomarkers on biosensor surfaces. Some of the examples analyzed include the following:1.Binding to and dissociation of different aptamer beacon modifications of interferon (IFN)-gamma in solution using fluorescence resonance energy transfer (FRET) and immobilized on an avidin-coated surface ([@bib69]).2.Binding and dissociation of Glutathione S-transferase fused to the N-terminus of a protein (GST-N) protein in Phosphate Buffered Saline (PBS) to a localized surface plasmon resonance coupled fluorescence (LSPCF) biosensor ([@bib37]).3.Binding of a cytochrome c mutant to an amperometric superoxide biosensor ([@bib75]).4.Binding of different concentrations (in micromoles) of carbonic anhydrase-II (CA-II) in solution to immobilized 4-(2-aminoethyl)-benzene sulfonamide (ABS) using signal-locking surface plasmon resonance (SPR) ([@bib76]).5.Binding to and dissociation from a microfluidic platform of 50 μM glycerol secreted from differentiated (murine 3T3) adipocytes ([@bib17]).6.Binding of different concentrations of C-reactive protein (CRP) to a new sandwich-type assay design using a label-free detection method.

Some of the other biomarker studies that have appeared in the recent literature or have been presented at conferences include the following:1.Alzheimer: a new theory ([@bib1]).2.Dual-Enzyme Biosensor for detection of organophosphorous compounds using organophosphorous Hydrolase and Horseradish Peroxide ([@bib78]).3.Multichannel mass organic analyzer and microfluidic networks for the automated in situ microchip electrophoretic analysis of organic biomarkers ([@bib79]).4.Hybrid magnetic-plasmonic nanoparticles for biomarkers ([@bib36]).5.Engineered Knottin peptides: a new class of agents for noninvasive molecular imaging of tumor biomarkers ([@bib7]).6.Identifying secreted biomarkers for murine evasion in cellular models of cancer ([@bib42]).7.SPR biosensor for parallelized detection of protein biomarkers in diluted blood plasma ([@bib59]).8.Biomarkers in drug discovery and development: from target identification through drug marketing ([@bib83]).9.Validation of analytic methods for biomarkers used in drug development ([@bib4]).10.Electrochemical biosensors: toward point-of-care diagnostics ([@bib74]).11.Biosensors for biomarkers in medical diagnostics ([@bib50]).12.Point-of-care biosensor systems for cancer diagnostics/prognostics ([@bib63]).13.The demonstration of the immunochemical biomarkers in methyl methacrylate-embedded plucked human hair follicles ([@bib5]).14.Surface plasmon resonance biosensor based on Vroman effect: toward cancer biomarker detection ([@bib17]).15.Biogenic nanoporous silica-based sensor for enhanced electrochemical detection of cardiovascular biomarker proteins ([@bib47]).16.Nanomonitor: a miniature electronic biosensor for glycan biomarker detection ([@bib52]).17.Multifunction dendrimer-template antibody presentation on biosensor surfaces for improved biomarker detection ([@bib34]).18.Rapid and sensitive detection of protein biomarker using a portable fluorescence biosensor based on quantum dots and a lateral flow strip ([@bib80]).20.A biomarker concept for assessment of insulin resistance, beta-cell function, and chronic system inflammation in type 2 diabetes mellitus ([@bib58]).21.Multifunctional Au nanoparticle dendrimer-based surface plasmon resonance biosensor and its application for improved insulin detection ([@bib27]).

Recently published reports are also available that describe in detail the different aspects of biomarkers and their applications in a clinical setting and the collaborative efforts that are required for their successful development ([@bib44]). For example, they include the highlights of key technologies that are required for the development of imaging biomarkers. More importantly, case studies are presented of individual imaging biomarkers. Finally, the future of imaging biomarkers is also presented.

We now use fractal analysis to analyze the binding and dissociation kinetics of some of the different biomarkers available in the open literature. The examples were selected at random, with no particular bias toward analyzing a particular biomarker, or a class of biomarkers.

11.2. Theory {#s0015}
============

[@bib180] has reviewed and analyzed the diffusion of reactants toward fractal surfaces. The details of the theory and the equations involved for the binding and the dissociation phases for analyte--receptor binding are available ([@bib183]). The details are not repeated here, except that the equations are given to permit an easier reading. These equations have been applied to other biosensor systems ([@bib183]; [@bib182]). For most applications, a single- or a dual-fractal analysis is often adequate to describe the binding and the dissociation kinetics. Peculiarities in the values of the binding and the dissociation rate coefficients, as well as in the values of the fractal dimensions with regard to the dilute analyte systems being analyzed will be carefully noted, if applicable.

In this chapter we analyze the binding and dissociation kinetics (if applicable) of (1) IFN-gamma as a function of aptamer variants and inclusion of spacer in addition to spacer ([@bib69]), (2) GST-N protein in PBS and GST-N protein in 10-fold diluted serum to an LPSCF fiber-optic biosensor ([@bib37]), (3) cytochrome c mutant to a superoxide biosensor ([@bib75]), (4) CA-II to an ABS ligand on an SPR biosensor surface ([@bib84]), (5) glycerol secretion from differentiated (murine 3T3-L1) adipocytes to a microfluidic platform for fluorescence-based assay ([@bib17]), and (6) different concentrations of CRP in solution to a sandwich-type assay using a label-free detection method, reflectometric interference spectroscopy ([@bib3]).

11.2.1. Single-Fractal Analysis {#s0020}
-------------------------------

### 11.2.1.1. Binding Rate Coefficient {#s0025}

[@bib179] indicates that the diffusion of a particle (analyte \[Ag\]) from a homogeneous solution to a solid surface (e.g., receptor \[Ab\]-coated surface) on which it reacts to form a product (analyte--receptor complex (Ab.Ag)) is given by$$\left( {Ab} \cdot {Ag} \right) \approx \begin{cases}
{t^{{({3 - D_{f,bind}})}/2} = t^{p}} & {t < t_{c}} \\
t^{1/2} & {t > t_{c}} \\
\end{cases}$$

Here D~f,bind~ or D~f~ (used later on in the chapter) is the fractal dimension of the surface during the binding step. t~c~ is the crossover value. [@bib179] indicates that the crossover value may be determined by r~c~ ^2^  ∼ t~c~. Above the characteristic length, r~c~, the self-similarity of the surface is lost and the surface may be considered homogeneous. Above time t~c~ the surface may be considered homogeneous, since the self-similarity property disappears, and "regular" diffusion is now present. For a homogeneous surface where D~f~  = 2, and when only diffusional limitations are present, p = ½ as it should be. Another way of looking at the p = ½ case (where D~f,bind~  = 2) is that the analyte in solution views the fractal object, in our case, the receptor-coated biosensor surface, from a "large distance." In essence, in the association process, the diffusion of the analyte from the solution to the receptor surface creates a depletion layer of width (Ðt)^½^ where Ð is the diffusion constant. This gives rise to the fractal power law (Analyte.Receptor) ∼  $t^{{({3 - D_{f,bind}})}/2}$. For the present analysis, t~c~ is arbitrarily chosen and we assume that the value of the t~c~ is not reached. One may consider the approach as an intermediate "heuristic" approach that may be used in the future to develop an autonomous (and not time-dependent) model for diffusion-controlled kinetics.

### 11.2.1.2. Dissociation Rate Coefficient {#s0030}

The diffusion of the dissociated particle (receptor \[Ab\] or analyte \[Ag\]) from the solid surface (e.g., analyte \[Ag\]--receptor \[Ab\] complex-coated surface) into solution may be given, as a first approximation by$$\left( {{Ab} \cdot {Ag}} \right) \approx - t^{{({3 - D_{f,diss}})}/2} = {-t}^{p}\quad\left( {t > t_{diss}} \right)$$

Here D~f,diss~ is the fractal dimension of the surface for the dissociation step. This corresponds to the highest concentration of the analyte--receptor complex on the surface. Henceforth, its concentration only decreases. The dissociation kinetics may be analyzed in a manner "similar" to the binding kinetics.

11.2.2. Dual-Fractal Analysis {#s0035}
-----------------------------

### 11.2.2.1. Binding Rate Coefficient {#s0040}

Sometimes, the binding curve exhibits complexities and two parameters (k, D~f~) are not sufficient to adequately describe the binding kinetics. This is further corroborated by low values of r^2^ factor (goodness of fit). In that case, one resorts to a dual-fractal analysis (four parameters; k~1~, k~2~, D~f1~, and D~f2~) to adequately describe the binding kinetics. The single-fractal analysis presented above is thus extended to include two fractal dimensions. At present, the time (t = t~1~) at which the "first" fractal dimension "changes" to the "second" fractal dimension is arbitrary and empirical. For the most part, it is dictated by the data analyzed and experience gained by handling a single-fractal analysis. A smoother curve is obtained in the "transition" region, if care is taken to select the correct number of points for the two regions. In this case, the product (antibody--antigen; or analyte--receptor complex, Ab.Ag or analyte.receptor) is given by$$\left( {{Ab} \cdot {Ag}} \right) \approx \begin{cases}
{t^{{({3 - D_{f1,bind}})}/2} = t^{p1}} & \left( t < t_{1} \right) \\
{t^{{({3 - D_{f2,bind}})}/2} = t^{p2}} & {\left( t_{1} < t < t_{2} \right) = t_{c}} \\
t^{1/2} & \left( t > t_{c} \right) \\
\end{cases}$$

In some cases, as mentioned above, a triple-fractal analysis with six parameters (k~1~, k~2~, k~3~, D~f1~, D~f2~, and D~f3~) may be required to adequately model the binding kinetics. This is when the binding curve exhibits convolutions and complexities in its shape due perhaps to the very dilute nature of the analyte (in some of the cases to be presented) or for some other reasons. Also, in some cases, a dual-fractal analysis may be required to describe the dissociation kinetics.

11.3. Results {#s0045}
=============

[@bib69] have developed an aptamer beacon for the detection of IFN-gamma, which is an important inflammatory cytokine. [@bib12] indicate that it is secreted by immune cells in response to various pathogens. [@bib69] indicate that the levels of this protein provide important information with regard to infectious diseases and the ability of the body to regulate an immune response. [@bib57] indicate that there is vigorous production of IFN-gamma in human immunodeficiency virus-infected patients. [@bib69] indicate that previous antibody-based detection techniques for IFN-gamma were very time consuming. [@bib39] indicates that aptamer-based affinity strategies are coming into prominence. [@bib25] indicate that aptamers are single-stranded DNA or RNA oligonucleotides that have been selected to bind to target analytes with high specificity and affinity. Aptamers have an advantage over antibodies since they are more robust; thus, aptamer-based biosensors can be regenerated and used over and over again. Furthermore, [@bib9], [@bib88], [@bib54], and [@bib49] indicate that aptamers are amenable to modification due to their simplicity and robustness. [@bib69] indicate that FRET may be used to convert aptamers into real-time biosensors ([@bib70]; [@bib8]).

[@bib81] and [@bib40] indicate that IFN-gamma is an important immune response marker. Thus, [@bib69] have designed a novel immune response marker to detect IFN-gamma. The DNA aptamer was biotinylated and immobilized on an SPR sensing surface by avidin--biotin interactions. The SPR biosensor was used to analyze the influence of biotinylation, fluorophore attachment, and spacer incorporation on the ability of the aptamer to bind to IFN-gamma.

IFN-gamma is a type II cytokine, and is critical for innate and adaptive immunity against viral and intracellular bacterial infections and for tumor control. Incorrect IFN-gamma expression is associated with a number of autoinflammatory and autoimmune diseases. It plays an important role in immunostimulatory and immunoregulatory effects. The IFN-gamma monomer consists of six alpha-helices and an extended unfolded chain in the C-terminal region ([@bib23], [@bib67]).

[@bib69] analyzed the influence of aptamer modification on the binding and dissociation of IFN-gamma in solution. [Figure 11.1(a)](#f0010){ref-type="fig"} shows the binding and dissociation of 100 nM IFN-gamma in solution to the modified aptamer 3′B (5′-GGG GTT GGT TGT GTT GGG TGT TGT GT-Biotin-3′; sequence with modification) beacon. A single-fractal analysis is adequate to describe the binding and the dissociation kinetics. The values of (1) the binding rate coefficient, k, and the fractal dimension for dissociation, D~f~, for binding and (2) the dissociation rate coefficient, k~d~, and the fractal dimension for dissociation, D~fd~ for a single-fractal analysis are given in [Table 11.1a](#t0010){ref-type="table"}, [Table 11.1b](#t0015){ref-type="table"} . [@bib69] indicate that the highest level of the cytokine (IFN-gamma) binding was observed for the modified aptamer 3′B.Figure 11.1Binding and dissociation of IFN-gamma in solution to different aptamer beacon modifications for fluorescence resonance energy transfer (FRET) and immobilized on an avidin-coated surface ([@bib69]): (a) B∗; (b) 3′BS, and (c) 5′BS.Table 11.1aBinding and Dissociation Rate Coefficients for Interferon (IFN)-Gamma as a Function of (a) Aptamer Variants and (b) Inclusion of Spacer in Addition to Biotin (BS) ([@bib69])Analyte/ReceptorAptamer Variantkk~1~k~2~k~d~IFN-gamma/aptamer beacon3′B75.790 ± 2.690NANA20.3111 ± 1.127IFN-gamma/aptamer beacon3′BS72.231 ± 3.407NANA3.934 ± 0.809IFN-gamma/aptamer beacon5″BS17.437 ± 0.880NANA13.682 ± 1.415IFN-gamma/aptamer + BSAptamer-B161.99 ± 12.6895.496 ± 7.926656.49 ± 1.1323.388 ± 2.514IFN-gamma/aptamer + BSF-aptamer-B166.65 ± 19.34104.54 ± 7.65509.19 ± 0.26236.330 ± 1.289Table 11.1bFractal Dimensions for the Binding and the Dissociation Phases for Interferon (IFN)-gamma as a Function of (a) Aptamer Variants and (b) Inclusion of Spacer in Addition to Biotin (BS) ([@bib69])Analyte/ReceptorAptamer variantD~f~D~f1~D~f2~D~fd~IFN-gamma/aptamer beacon3′B2.1364 ± 0.0416NANA1.9914 ± 0.0414IFN-gamma/aptamer beacon3′BS2.3058 ± 0.0560NANA1.4332 ± 0.1402IFN-gamma/aptamer beacon5′BS2.3238 ± 0.04372NANA2.3082 ± 0.1082IFN-gamma/aptamer + BSAptamer-B2.3854 ± 0.1022.0568 ± 0.11672.9747 ± 0.008242.1812 ± 0.07782IFN-gamma/aptamer + BSF-aptamer-B2.4808 ± 0.089562.1906 ± 0.10342.9531 ± 0.002472.9358 ± 0.02646

[@bib69] also included a polyethylene glycol spacer between the aptamer and the biotin so that the nucleotides could be more accessible to the target analyte. [Figure 11.1(b)](#f0010){ref-type="fig"} shows the binding of 100 nM IFN-gamma to a 3′BS (5′-GGG GTT GGT TGT GTT GGG TGT TGT GT-C12-Biotin-3′) modified aptamer beacon. In this case, in addition to the biotin (B) a spacer was included (BS). Once again, a single-fractal analysis is adequate to describe the binding and the dissociation kinetics. The values of (1) the binding rate coefficient, k, and the fractal dimension, D~f~, and (2) the dissociation rate coefficient, k~d~, and the fractal dimension for dissociation, D~fd~, for a single-fractal analysis are given in [Table 11.1a](#t0010){ref-type="table"}, [Table 11.1b](#t0015){ref-type="table"}. It is of interest to note that as one goes from the modified aptamer beacon 3′B to the modified aptamer beacon 3′BS the binding rate coefficient, k, decreases by 4% from a value of k = 75.79 to k = 72.231, and the fractal dimension, D~f~, increases by a factor of 1.079 from a value of D~f~  = 2.1364 to D~f~  = 2.3058. In this case, changes in the fractal dimension (degree of heterogeneity on the biosensor surface) and in the binding rate coefficient are in opposite directions ([Table 11.1a](#t0010){ref-type="table"}, [Table 11.1b](#t0015){ref-type="table"}).

[Figure 11.1(c)](#f0010){ref-type="fig"} shows the binding of 100 nM IFN-gamma in solution to the 5′BS(5′-Biotin-C12-GGG GTT GGT TGT GTT GGG TGT TGT Gt-3′) modified aptamer beacon. Once again, a single-fractal analysis is adequate to describe the binding and the dissociation kinetics. The values of (a) the binding rate coefficient, k, and the fractal dimension, D~f~, and (b) the dissociation rate coefficient, k~d~, and the fractal dimension for dissociation, D~fd~, are given in [Table 11.1a](#t0010){ref-type="table"}, [Table 11.1b](#t0015){ref-type="table"}. Note that in this case there is an increase in the fractal dimension, D~f~ (the highest when compared with the B′ and B'S aptamer modifications), and a decrease in the binding rate coefficient, k (the lowest when compared with B′ and B'S aptamer modifications). In this case, there is a substantial decrease in the binding rate coefficient, k. The decrease is higher than a factor of four.

[Figure 11.2(a)](#f0015){ref-type="fig"} and [Table 11.1a](#t0010){ref-type="table"}, [Table 11.1b](#t0015){ref-type="table"} show the increase in the binding rate coefficient, k, for a single-fractal analysis with an increase in the fractal dimension, D~f~. For the data shown in [Figure 11.2(a)](#f0015){ref-type="fig"}, the binding rate coefficient, k, is given by$$k = \left( 1.552 \pm 1.342 \right)\ \left( D_{f} \right)^{3.01 \pm 1.81}$$ Figure 11.2(a) Increase in the binding rate coefficient, k, with an increase in the fractal dimension, D~f~, for a single-fractal analysis. (b) Increase in the affinity, K (=k/k~d~), with an increase in the fractal dimension ratio, D~f~/D~fd~, for a single-fractal analysis.

The fit is reasonable. Only three data points are available. The availability of more data points would lead to a more reliable fit. The binding rate coefficient, k, exhibits close to a third (equal to 3.01) order of dependence on the fractal dimension, D~f~, that exists on the biosensor surface. This indicates that the binding rate coefficient, k, is sensitive to the fractal dimension, D~f~, or the degree of heterogeneity that exists on the biosensor surface ([Table 11.1a](#t0010){ref-type="table"}, [Table 11.1b](#t0015){ref-type="table"}).

[Figure 11.2(b)](#f0015){ref-type="fig"} and [Table 11.1a](#t0010){ref-type="table"}, [Table 11.1b](#t0015){ref-type="table"} show the increase in the affinity, K (=k/k~d~), for a single-fractal analysis with an increase in the fractal dimension ratio, D~f~/D~fd~. For the data shown in [Figure 11.2(b)](#f0015){ref-type="fig"}, the affinity, K, is given by$$K\ \left( = k/k_{d} \right) = \left( 1.740 \pm 1.282 \right)\ \left( D_{f}/D_{fd} \right)^{5.064 \pm 1.498}$$

The fit is very good. Only three data points are available. The availability of more data points would lead to a more reliable fit. The affinity, K (k/k~d~), is very sensitive to the fractal dimension ratio (D~f~/D~fd~) as it exhibits close to a fifth (equal to 5.064) order of dependence on the fractal dimension ratio (D~f~/D~fd~). This is a very convenient way of manipulating the affinity, K, by changing the heterogeneity of the biosensor surface. Some ingenuity may be required here, since a change in the degree of heterogeneity on the biosensor surface would change both the binding as well as the dissociation rate coefficients.

[Figure 11.3(a)](#f0020){ref-type="fig"} shows the binding of the IFN-gamma to the biotin + aptamer B variant ([@bib69]). Once again, a dual-fractal analysis is required to describe the binding kinetics. A single-fractal analysis is adequate to describe the dissociation kinetics. The values of (1) the binding rate coefficient, k, and the fractal dimension, D~f~, for a single-fractal analysis, (2) the binding rate coefficients, k~1~ and k~2~, and the fractal dimensions, D~f1~ and D~f2~, for a dual-fractal analysis, and (3) the dissociation rate coefficient, k~d~, and the fractal dimension for dissociation, D~fd~, for a single-fractal analysis are given in [Table 11.1a](#t0010){ref-type="table"}, [Table 11.1b](#t0015){ref-type="table"}. In this case, the affinity values K~1~ (=k~1~/k~d~) and K~2~ (=k~2~/k~d~) are 4.083 and 28.07, respectively ([Table 11.1a](#t0010){ref-type="table"}, [Table 11.1b](#t0015){ref-type="table"}).

Note that for dual-fractal analysis for the binding phase, an increase in the fractal dimension by 44.6% from a value of D~f1~  = 2.0568 to D~f2~  = 2.947 leads to an increase in the binding rate coefficient by a factor of 6.87 from a value of k~1~  = 95.496 to k~2~  = 656.49.

[@bib69] also investigated the influence of a fluorophore (F) in addition to the biotin for the modified aptamer B during the binding of IFN-gamma. This was one of the aptamer variants. [Figure 11.3(b)](#f0020){ref-type="fig"} shows that a dual-fractal analysis is required to describe the binding kinetics. A single-fractal analysis is adequate to describe the dissociation kinetics. The values of (1) the binding rate coefficient, k, and the fractal dimension, D~f~, for a single-fractal analysis, (2) the binding rate coefficients, k~1~ and k~2~, and the fractal dimensions, D~f1~ and D~f2~, for a dual-fractal analysis, and (3) the dissociation rate coefficient, k~d~, and the fractal dimension for dissociation, D~fd~, for a single-fractal analysis are given in [Table 11.1a](#t0010){ref-type="table"}, [Table 11.1b](#t0015){ref-type="table"}. The affinity values K~1~ (=k~1~/k~d~) and K~2~ (=k~2~/k~d~) are 2.87 and 14.02, respectively. Figure 11.3Binding and dissociation of (interferon) IFN-gamma in solution to aptamer-B ([@bib69]): (a) Aptamer  + BS; (b) aptamer + BS + spacer.

Note that for dual-fractal analysis for the binding phase, an increase in the fractal dimension by 34.8% from a value of D~f1~  = 2.1906 to D~f2~  = 2.9531 leads to an increase in the binding rate coefficient by a factor of 4.87 from a value of k~1~  = 104.54 to k~2~  = 509.19 ([Table 11.1a](#t0010){ref-type="table"}, [Table 11.1b](#t0015){ref-type="table"}).

Also, note that on comparing the affinity values K~1~ and K~2~ when the fluorophore is used and not used, the K~1~ value is slightly lower and the K~2~ value is significantly higher (by about 28%), respectively.

[@bib37] have developed a localized LSPCF fiber-optic biosensor for the detection of severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in human serum. These authors indicate that SARS is a highly infectious disease. [@bib9003] indicate that SARS results in death in a large portion of patients. The SARS coronavirus (SARS-CoV) causes SARS, and is detectable in the respiratory secretions of patients after infection ([@bib9004]). [@bib82] emphasize that SARS is highly contagious and exhibits the potential of becoming a large-scale future epidemic if effective therapeutic drugs are not discovered. [@bib87] and [@bib9001] emphasize the need for a rapid, sensitive, specific, and an accurate diagnostic method so that specific patients may be correctly assessed.

[@bib37] indicate that there are methods available to detect SARS. However, present methods such as reverse transcriptase polymerase chain reaction are not sensitive enough, and also require a specific laboratory with expertise in molecular diagnostics to confirm SARS in the acute phase ([@bib9005], [@bib9003] ).Figure 11.5Binding of different concentrations of GST-N (in picomoles per milliliter) in 10-fold diluted human serum ([@bib15]): (a) 1000; (b) 100; (c) 10.

[@bib37] indicate that gold nanoparticles (GNPs) have been introduced into biosensing ([@bib9006], [@bib9002]). These GNPs possess special properties such as localized surface plasmons. [@bib37] have developed a novel fiber-optic biosensor where the property of LSPCF has been combined with the sandwich immunoassay. [@bib37] have used their LSPCF fiber-optic biosensor to detect SARS-CoV protein in diluted serum to a limit of 1 pg/ml. This according to these authors exhibits the potential for the early detection of clinical SARS-CoV infection.

[Figure 11.4](#f0025){ref-type="fig"} shows the binding of l000 pg/ml GST-N protein in solution to the LSPCF biosensor ([@bib37]). A single-fractal analysis is required to describe the binding kinetics. The values of (a) the binding rate coefficient, k and the fractal dimension, D~f~ for a single-fractal analysis are given in [Table 11.2a](#t0020){ref-type="table"}, [Table 11.2b](#t0025){ref-type="table"} . Figure 11.4Binding of 1000 pg/ml GST-N protein in PBS to an LSPCF (localized surface plasmon coupled fluorescence) biosensor ([@bib15]).Table 11.2aBinding Rate Coefficients for (a) GST-N Protein in PBS and (b) GST-N Protein in 10-Fold Diluted Human Serum to an LSPCF Fiber-Optic Biosensor ([@bib15])Analyte in Solution/Receptor on Surfacekk~1~k~2~1000 pg/ml GST-N protein in PBS/LSPCF probe0.00728 ± 0.00241NANA1000 pg/ml GST-N protein in 10-fold diluted human serum/LSPCF probe0.01344 ± 0.005980.007192 ± 0.002050.1615 ± 0.0001100 pg/ml GST-N protein in 10-fold diluted human serum/LSPCF probe0.03951 ± 0.014350.01768 ± 0.00070.07217 ± 0.0004510 pg/ml GST-N protein in 10-fold diluted human serum/LSPCF probe0.02934 ± 0.013630.002714 ± 0.0006700.1436 ± 0.00145[^1]Table 11.2bFractal Dimensions in the Binding Phase for (a) GST-N Protein in PBS and (b) GST-N Protein in 10-Fold Diluted Human Serum to an LSPCF Fiber-Optic Biosensor ([@bib15])Analyte in Solution/Receptor on SurfaceD~f~D~f1~D~f2~1000 pg/ml GST-N protein in PBS/LSPCF probe1.6224 ± 0.1154NANA1000 pg/ml GST-N protein in 10-fold diluted human serum/LSPCF probe1.9782 ± 0.19121.4938 ± 0.25523--0.0060100 pg/ml GST-N protein in 10-fold diluted human serum/LSPCF probe2.9632 ± 0.13651.0502 ± 0.009413--0.0048410 pg/ml GST-N protein in 10-fold diluted human serum/LSPCF probe1.5912 ± 0.20540.2082 ± 0.62163--0.4444[^2]

[@bib37] prepared GST-N protein samples in 10-fold diluted human serum. This allowed them to test their LSPCF biosensor in clinical samples. They measured the temporal fluorescence intensity of the biomolecular interaction between the LSPCF probes and the GST-N protein. They did this for the 10--1000 pg/ml rages GST-N protein in solution.

[Figure 11.5(a)](#f0030){ref-type="fig"} shows the binding of 1000 pg/ml GST-N protein in 10-fold diluted human serum in solution. A dual-fractal analysis is required to adequately describe the binding kinetics. The values of (a) the binding rate coefficient, k and the fractal dimension, D~f~ for a single fractal analysis, and (b) the binding rate coefficients, k~1~ and k~2~, and the fractal dimensions, D~f1~ and D~f2~ for a dual-fractal analysis are given in [Table 11.2a](#t0020){ref-type="table"}, [Table 11.2b](#t0025){ref-type="table"}. For a dual-fractal analysis, an increase in the fractal dimension by a factor of 2.00 from a value of D~f1~ equal to 1.4938 to D~f2~ equal to 3.0 leads to an increase in the binding rate coefficient by a factor of 22.45 from a value of k~1~ equal to 0.007192 to k~2~ equal to 0.1615. Once again, an increase in the fractal dimension or the degree of heterogeneity on the LSPCF biosensor surface leads to an increase in the binding rate coefficient.

[Figure 11.5(b)](#f0030){ref-type="fig"} shows the binding of 100 pg/ml GST-N protein in 10-fold diluted human serum in solution. Once again, a dual-fractal analysis is required to adequately describe the binding kinetics. The values of (a) the binding rate coefficient, k and the fractal dimension, D~f~ for a single fractal analysis, and (b) the binding rate coefficients, k~1~ and k~2~, and the fractal dimensions, D~f1~ and D~f2~ for a dual-fractal analysis are given in [Table 11.2a](#t0020){ref-type="table"}, [Table 11.2b](#t0025){ref-type="table"}. For a dual-fractal analysis, an increase in the fractal dimension by a factor of 2.86 from a value of D~f1~ equal to 1.0502 to D~f2~ equal to 3.0 leads to an increase in the binding rate coefficient by a factor of 4.08 from a value of k~1~ equal to 0.01768 to k~2~ equal to 0.07217. Once again, an increase in the fractal dimension or the degree of heterogeneity on the LSPCF biosensor surface leads to an increase in the binding rate coefficient.

[Figure 11.5(c)](#f0030){ref-type="fig"} shows the binding of 10 pg/ml GST-N protein in 10-fold diluted human serum in solution. A dual-fractal analysis is required to adequately describe the binding kinetics. The values of (a) the binding rate coefficient, k and the fractal dimension, D~f~ for a single fractal analysis, and (b) the binding rate coefficients, k~1~ and k~2~, and the fractal dimensions, D~f1~ and D~f2~ for a dual-fractal analysis are given in [Table 11.2a](#t0020){ref-type="table"}, [Table 11.2b](#t0025){ref-type="table"} once again, for a dual-fractal analysis, an increase in the fractal dimension by a factor of 14.4 from a value of D~f1~ equal to 0.2082 to D~f2~ equal to 3.0 leads to an increase in the binding rate coefficient by a factor of 52.9 from a value of k~1~ equal to 0.002714 to k~2~ equal to 0.1436. Once again, an increase in the fractal dimension or the degree of heterogeneity on the LSPCF biosensor surface leads to an increase in the binding rate coefficient.

[Table 11.2a](#t0020){ref-type="table"}, [Table 11.2b](#t0025){ref-type="table"} show for a dual-fractal analysis the increase in the fractal dimension, D~f~ with an increase in the GST-N protein concentration in solution in the 10--1000 pg/ml range. Figure not shown. For the data shown in [Table 11.2](#t0020){ref-type="table"} the fractal dimension, D~f~ is given by:$$D_{f1} = \left( 0.09843 \pm 0.0794 \right)\mspace{9mu}\left\lbrack {GST} - N \right\rbrack^{0.420 \pm 0.164}$$

The fit is reasonable. Only three data points are available. The availability of more data points would lead to a more reliable fit. The fractal dimension, D~f1~ exhibits less than one-half (equal to 0.420) order of dependence on the GST-N protein concentration in solution in the 10--1000 pg/ml range. This indicates that the fractal dimension, D~f1~ exhibits a mild dependence on the GST-N protein concentration in solution.

The superoxide anion radical is present in several pathophysiological situations, such as sepsis ([@bib72], [@bib73]). Electrochemical biosensors can detect this short-lived species ([@bib45], [@bib61]). [@bib75] indicate that the redox protein cytochrome c is used as a recognition element. These authors indicate that superoxide dismutase (SOD) biosensors used for the detection of the superoxide anion often lack the reproducibility due to immobilization problems. However, cyt c-based superoxide biosensors are more stable and may be used in *in vivo* applications ([@bib14], [@bib62]). In this case, the heme protein is reduced by the superoxide, followed by reduction by an electrode.

[@bib75] indicate that short-chain modified gold electrodes exhibit a highly efficient communication between cyt c and the electrode ([@bib28], [@bib35], [@bib53], [@bib66]). They have been used for cyt c based superoxide sensors. [@bib75] analyzed the effect of introducing positive charges (lysines) in human cytochrome c on the redox properties and reaction rates of cyt c with superoxide radicals.

These authors claim that the eleven mutants analyzed were modified for structural integrity as well as axial coordination of the heme ion. Their results indicate that four mutants exhibited a higher reaction rate with the radical as compared with the wild type. These mutants were then used for the construction of the superoxide biosensors.

[Figure 11.6](#f0035){ref-type="fig"} shows the binding of cyt c in solution to the superoxide biosensor ([@bib75]). A single-fractal analysis is adequate to describe the binding kinetics. The binding rate coefficient, k and the fractal dimension, D~f~, for a single-fractal analysis are 0.2109 ± 0.0302, and 1.234 ± 0.1806, respectively. These results are also shown in [Table 11.3a](#t0030){ref-type="table"}, [Table 11.3b](#t0035){ref-type="table"} . A single-fractal analysis is also adequate to describe the dissociation kinetics. The values of the dissociation rate coefficient, k~d~ and the fractal dimension, D~fd~ are 0.00116 ± 0.00015 and 0.3666 and 0.14702, respectively. In this case the affinity, K (=k/k~d~) is equal to 181.81. Figure 11.6Binding of a cytochrome c mutant to an amperometric superoxide biosensor ([@bib29]).Table 11.3aBinding and Dissociation Rate Coefficients for (a) Cytochrome c Mutant to a Superoxide Biosensor ([@bib29]) and (b) Binding of Carbonic Anhydrase-II (CA-II) to a 4-(2-Aminoethyl)-Benzene Sulfonamide (ABS) Ligand on an Surface Plasmon Resonance (SPR) Biosensor Surface ([@bib79])Analyte in Solution/Receptor on surfacekk~1~k~2~k~d~ReferenceCytochrome c mutant/superoxide biosensor0.2109 ± 0.0302NANA0.00116 ± 0.00015[@bib29]2.3 μM CA-II/4-(2-aminoethyl-benzene sulfonamide (ABS) ligand40.359 ± 5.60420.817 ± 1.416120.16 ± 0.0283NA[@bib30]5.3 μM CA-II/4-(2-aminoethyl-benzene sulfonamide (ABS) ligand116.76 ± 7.7783.718 ± 4.847152.87 ± 0.46NA[@bib30]11.0 μM CA-II/4-(2-aminoethyl-benzene sulfonamide (ABS) ligand98.584 ± 9.46839.916 ± 8.403238.66 ± 0.351NA[@bib30]Table 11.3bFractal Dimensions for the Binding and the Dissociation Phases for (a) Cytochrome c Mutant to a Superoxide Biosensor ([@bib29]), and (b) Binding of Carbonic Anhydrase-II (CA-II) to a 4-(2-Aminoethyl)-Benzene Sulfonamide (ABS) Ligand on an (Surface Plasmon Resonance) SPR Biosensor Surface ([@bib79])Analyte in Solution/Receptor on SurfaceD~f~D~f1~D~f2~D~fd~ReferencesCytochrome c mutant/superoxide biosensor1.2334 ± 0.1806NANA0.3666 ± 0.1470[@bib29]2.3 μM CA-II/4-(2-aminoethyl-benzene sulfonamide (ABS) ligand2.5114 ± 0.08022.1364 ± 0.07852.4698 ± 0.00412NA[@bib30]5.3 μM CA-II/4-(2-aminoethyl-benzene sulfonamide (ABS) ligand1.1336 ± 04102.6146 ± 0.08202.9294 ± 0.00692NA[@bib30]11.0 μM CA-II/4-(2-aminoethyl-benzene sulfonamide (ABS) ligand1.205 ± 0.0751.9670 ± 0.27862.9807 ± 0.0019NA[@bib30]

[@bib76] have recently analyzed low noise detection of biomolecular interactions with signal-locking surface plasmon resonance. Surface plasmon resonance is a popular technique to analyze biomolecular interactions at a surface, especially since it is label-free. These authors indicate that the SPR technique is subject to the influence of noise and drift disturbances since that limits the minimum detectable mass change. The SPR technique uses the step response of the biomolecular interactions occurring on the biosensor surface. The technique proposed by [@bib76] measures the biomolecular interactions over a very narrow frequency range. This locks the measured response to a very specific narrow band signal. The authors used their technique to analyze the binding kinetics of carbonic anhydrase-II (CA-II) and immobilized 4-(2-aminoethyl)-benzenesulfonamide (ABS) to a SPR surface.

Carbonic anhydrases are a family of enzymes that catalyze the rapid conversion of carbon dioxide and water to bicarbonate and protons. These anhydrases are classified as metalloenzymes since the active site of most carbonic anhydrases contains a zinc ion. The primary function of this enzyme in animals is to maintain the acid-base balance in blood and other tissues, and to help transport carbon dioxide out of tissues. Carbon anhydrase II is a novel biomarker for gasterointestinal stomal tumors ([@bib56]). These authors indicate that various carbonic anhydrase (CA) isoenzymes have been identified as potential targets against different cancers. They further indicate that high CA-II expression is associated with a better disease specific survival rate than low or no expression.

[Figure 11.7(a)](#f0040){ref-type="fig"} shows the binding of 2.3μM CA-II anhydrase in solution to a 4-(2-amino ethyl)-benzene sulfonamide (ABS) ligand on a SPR biosensor surface ([@bib84]). A dual-fractal analysis is required to adequately describe the binding kinetics. The values of (a) the binding rate coefficient, k and the fractal dimension, D~f~ for a single fractal analysis, and (b) the binding rate coefficients, k~1~ and k~2~, and the fractal dimensions, D~f1~ and D~f2~ for a dual-fractal analysis are given in [Table 11.3a](#t0030){ref-type="table"}, [Table 11.3b](#t0035){ref-type="table"}. It is of interest to note that as the fractal dimension increase by a factor of 1.156 from a value of D~f1~ equal to 2.1364 to D~f2~ equal to 2.4698, the binding rate coefficient increases by a factor of 5.95 from a value of k~1~ equal to 20.817 to k~2~ equal to 120.16.Figure 11.7Binding of different concentrations (in micromoles) of carbonic anhydrase-II (CA-II) analyte in solution to immobilized 4-(2-aminoethyl)-benzene sulfonamide (ABS) using signal-locking surface plasmon resonance ([@bib30]): (a) 2.3; (b) 5.3; (c) 11.0.

[Figure 11.7(b)](#f0040){ref-type="fig"} shows the binding of 5.3μM CA-II anhydrase in solution to a 4-(2-amino ethyl)-benzene sulfonamide (ABS) ligand on a SPR biosensor surface (Williams et al., 2009). Once again, a dual-fractal analysis is required to adequately describe the binding kinetics. The values of (a) the binding rate coefficient, k and the fractal dimension, D~f~ for a single fractal analysis, and (b) the binding rate coefficients, k~1~ and k~2~, and the fractal dimensions, D~f1~ and D~f2~ for a dual-fractal analysts are given in [Table 11.3a](#t0030){ref-type="table"}, [Table 11.3b](#t0035){ref-type="table"}. It is of interest to note that as the fractal dimension increase by a factor of 1.12 from a value of D~f1~ equal to 2.6146 to D~f2~ equal to 2.9294, the binding rate coefficient increases by a factor of 1.826 from a value of k~1~ equal to 83.718 to k~2~ equal to 152.87.

[Figure 11.7(c)](#f0040){ref-type="fig"} shows the binding of 11.0μM CA-II anhydrase in solution to a 4-(2-amino ethyl)-benzene sulfonamide (ABS) ligand on a SPR biosensor surface (Williams et al., 2009). Once again, a dual- fractal analysis is required to adequately describe the binding kinetics. The values of (a) the binding rate coefficient, k and the fractal dimension, D~f~ for a single fractal analysis, and (b) the binding rate coefficients, k~1~ and k~2~, and the fractal dimensions, D~f1~ and D~f2~ for a dual-fractal analysis are given in [Table 11.3a](#t0030){ref-type="table"}, [Table 11.3b](#t0035){ref-type="table"} It is of interest to note that as the fractal dimension increase by a factor of 1.515 from a value of D~f1~ equal to 1.967 to D~f2~ equal to 2.9807, the binding rate coefficient increases by a factor of 5.98 from a value of k~1~ equal to 39.916 to k~2~ equal to 238.66.

[Figure 11.8(a)](#f0045){ref-type="fig"} and [Table 11.3(a)](#t0030){ref-type="table"} show the increase in the binding rate coefficient, k~2~ with an increase in the CA-II concentation in solution in the 2.3--11μM range. For the data shown in [Figure 11.8(a)](#f0045){ref-type="fig"}, the binding rate coefficient, k~2~, is given by:$$k_{2} = \left( 80.452 \pm 8.66 \right)\ \left\lbrack {CA} - {II} \right\rbrack^{0.435 \pm 0.092}$$ Figure 11.8(a) Increase in the binding rate coefficient, for a dual-fractal analysis with an increase in the carbonic anhydrase II (CA-II) concentration (in micromoles) in solution. (b) Increase in the fractal dimension, D~f~, with an increase in the carbonic anhydrase-II (CA-II) concentration (CA-II) (in micromoles) in solution. (c) Increase in the binding rate coefficient, k~2~, with an increase in the fractal dimension, D~f2~. (d) Increase in the binding rate coefficient ratio, k~2~/k~1~, with an increase in the fractal dimension ratio, D~f2~/D~f1~. (e) Increase in the fractal dimension ratio, D~f2~/D~f1~, with an increase in the carbonic anhydrase-II (CA-II) concentration (in micromoles) in solution.

The fit is good. Only three data points are available. The availability of more data points would lead to a more reliable fit. The binding rate coefficient, k~2~ exhibits less than one-half (equal to 0.435) order of dependence on the CA-II concentration in solution in the 2.3--11.0 μM range. This indicates that the binding rate coefficient, k~2~ is only mildly sensitive to the CA-II concentration in solution.

[Figure 11.8(b)](#f0045){ref-type="fig"} and [Table 11.3(a)](#t0030){ref-type="table"} show the increase in the fractal dimension D~f2~, p with an increase in the CA-II concentration in solution in the 2.3--11 μM range. For the data shown in [Figure 11.8(b)](#f0045){ref-type="fig"}, the fractal dimension, D~f2~ is given by:$$D_{f2} = \left( 2.279 \pm 0.130 \right)\left\lbrack {CA} - {II\rbrack} \right.^{0{.122} \pm 0{.050}}$$

The fit is good. Only three data points are available. The availability of more data points would lead to a more reliable fit. The fractal dimension, D~f2~ exhibits a very mild dependence (equal to 0.122; close to zero order) on the CA-II concentration in solution in the 2.3--11.0 μM range. This indicates that the fractal dimension, D~f2~ is only mildly sensitive to the CA-II concentration in solution. The fractal dimension is based on a log scale, and even small changes in the fractal dimension indicate a reasonable change in the degree of heterogeneity on the biosensor surface.

[Figure 11.8(c)](#f0045){ref-type="fig"} and [Table 11.3a](#t0030){ref-type="table"}, [Table 11.3b](#t0035){ref-type="table"} show the increase in the binding rate coefficient, k~2~ with an increase in the fractal dimension, D~f2~. For the data shown in [Figure 11.8(b)](#f0045){ref-type="fig"}, the binding rate coefficient, k~2~ is given by:$$k_{2} = (106.50 \pm 15.12)D_{f2}^{2.011 \pm 0.561}$$

The fit is good. Only three data points are available. The availability of mora data points would lead to a more reliable fit. The binding rate coefficient, k~2~ exhibits close to a second (equal to 2.011) order of dependence on the fractal dimension, D~f2~ This indicates that the binding rate coefficient, k~2~ is sensitive to the fractal dimension, D~f2~ or the degree of heterogeneity on the biosensor surface.

[Figure 11.8(d)](#f0045){ref-type="fig"} and [Table 11.3a](#t0030){ref-type="table"}, [Table 11.3b](#t0035){ref-type="table"} show the increase in the binding rate coefficient ratio, k~2~/k~1~ with an increase in the fractal dimension ratio D~f2~/D~f1.~ For the data in [Figure 11.8(d)](#f0045){ref-type="fig"} the binding rate coefficient ration k~2~/k~1~ is given by:$$k_{2}/k_{1} = (1.549 \pm 0.530\rbrack{D_{f2}/D_{f1}^{3.386 \pm 1.249}}$$

The fit is good. Only three data points are available. The availability of more data points would lead to a more reliable fit. The binding rate coefficient ratio, k~2~/k~1~ exhibits an order of dependence between three and three and one half (equal to 3.386) on the ratio of the fractal dimensions, D~f2~/D~f1~. This indicates that the binding rate coefficient ratio is very sensitive to the fractal dimension ratio

[Figure 11.8(e)](#t0045){ref-type="table"} shows the increase in the ratio of the binding rate coefficient, D~f2~/D~f1~ with an increase in the CA-II concentration in solution. The ratio, D~f2~/D~f1~ is only mildly dependent on the CA-II concentration in solution.

[@bib85] have recently developed a continuous-flow enzyme assay on a microfluidic chip for monitoring glycerol secretion from cultivated adipocytes. These authors indicate that different studies on using chips to monitor cellular secretion have appeared in the literature ([@bib15], [@bib46]; [@bib24], [@bib41], [@bib51], [@bib71]). [@bib85] indicate that physiological studies need to maintain cells or tissues in a controlled environment as one detects their physical, electrical and mechanical properties. These authors indicate micriofluidics facilitates such situations, since they permit creation of highly controlled cell-compatible environments along with measurement and cell maniplation methods.

[@bib85] emphasize that the prevalence of obesity-related disorders underscores the need to adipocyte physiology. Adipocytes store and release energy. Adipocytes store energy as triacylglycerol by lipolysls. Ths supplies energy for tissues and organs. [@bib86] and [@bib30], [@bib31] indicate that the measurement of glycerol is used to determine the function and physiological state of adipocytes. [@bib85] have developed a dual-chip microfluidic system for culturing adipocytes and then monitoring the glycerol using a continuous fluorescent enzyme assay after a perfusion step. The authors used their system to demonstrate transient increases in glycerol secretion during exposure of the cells to isoproterenol, a β-adrenergic agonist. These adrenergic agonists act on receptors.

Beta receptors are specific molecules found in the body which receive and process signals for the nervous system and various hormones. These beta receptors are located at many places in the body, but are found in high numbers in the heart and blood vessels. Here they increase blood pressure when stimulated. Thus, they are attractive targets for high blood pressure treatment.

[@bib85] analyzed the glycerol secretion data from differentiated adipocytes and response to isoproterenol treatment. [Figure 11.9(a)](#f0050){ref-type="fig"} shows the binding of glycerol secretion from differentiated (murine 3T3-L1) adipocytes by a continuous-flow enzyme assay on a microfluidic chip. A dual-fractal analysis is required to model the binding and the dissociation kinetics. The values of (a) the binding rate coefficient, k and the fractal dimension, D~f~ for a single-fractal analysis, (b) the binding rate coefficients, k~1~ and k~2~ and the fractal dimensions, D~f1~ and D~f2~ for a dual-fractal analysis, (c) the dissociation rate coefficient, k~d~ and the fractal dimension, D~fd~ for a single-fractal analysis, and (d) the dissociation rate coefficients, k~d1~ and k~d2~ and the fractal dimensions for the dissociation phase, D~fd1~ and D~fd2~ for a dual-fractal analysis are given in [Table 11.4a](#t0040){ref-type="table"}, [Table 11.4b](#t0045){ref-type="table"} .Figure 11.9(a) Binding and dissociation of 50 μM glycerol secreted from differentiated (murine 3T3-L1) adipocytes to a microfluidic platform ([@bib6]): (b) same as in; (a) but isoproterenol added.Table 11.4aBinding and Dissociation Rate Coefficients for Glycerol Secretion from (a) Differentiated (Murine 3T3-L1) Adipocytes to a Microfluidic Platform for Fluorescence-Based Enzyme Assay and (b) Influence of Isoproterenol on Online Enzyme Assay for Glycerol ([@bib6])Analyte/Receptorkk~1~k~2~k~d~k~d1~k~d2~Glycerol from differentiated (murine 3T3-L1) adipocytes/microfluidic platform40.25 ± 12.1154.74 ± 14.2923.64 ± 3.44528.689 ± 8.23936.862 ± 1.1870.6187 ± 0.8260Influence of isoproterenol on 50 μL glycerol/online enzyme assay3.113 ± 0.09340.4301 ± 0.18725.061 ± 0.1752.4653 ± 0.8981NANATable 11.4bFractal Dimensions for the Binding and the Dissociation Phases for Glycerol Secretion from (a) Differentiated (Murine 3T3-L1) Adipocytes to a Microfluidic Platform for Fluorescence-Based Enzyme Assay and (b) Influence of Isoproterenol on Online Enzyme Assay for Glycerol ([@bib6])Analyte/ReceptorD~f~D~f1~D~f2~D~fd~D~fd1~D~fd2~Glycerol from differentiated (murine 3T3-L1) adipocytes/microfluidic platform2.065 ± 0.6351.9440 ± 0.3901.3358 ± 0.23040.288 ±0.1880+0.03880Influence of isoproterenol on 50 μl glycerol/online enzyme assay1.7176 ± 0.47360 + 1.94461.7570 ± 0.14522.6102 ± 0.4192NANA

[Figure 11.9(b)](#f0050){ref-type="fig"} shows the binding of glycerol secretion from differentiated (murine 3T3-L1) adipocytesin the presence of iso proterenol by a continuous-flow enzyme assay on a microfluidic chip. A dual-fractal analysis is required to model the binding and the dissociation kinetics. The values of (a) the binding rate coefficient, k and the fractal dimension, D~f~ for a single-fractal analysis, (b) the binding rate coefficients, k~1~and k~2~ and the fractal dimensions, D~f1~ and D~f2~ for a dual-fractal analysis, and (c) the dissociation rate coefficient, k~d~ and the fractal dimension, D~fd~ for a single-fractal analysis are given in [Table 11.4a](#t0040){ref-type="table"}, [Table 11.4b](#t0045){ref-type="table"}.

[@bib3] have recently presented a new assay design for clinical diagnostics based on alternative recognition. These indicate that the assay format has an important impact in the practical handling as well in the sensitivity of the testing results. [@bib38] indicate that for clinical diagnostics the sandwich assay format is frequently used due to (a) its lower limits of detection compared to other formats, (b) and reliable analysis of the different parameters. [@bib3] further indicate that a drawback of the sandwich assay format is the need for immobilization of the capture antibody on the surface. This often results in a significant loss in binding activity. Also, there is no guarantee that the binding sites on the antibodies immobilized on the surface are oriented in the 'correct' direction. This hinders the biosensor performance parameters such as sensitivity, loss in function, and stability of the sensor surface. In essence, these authors indicate that the recognition element on the sensor surface needs to exhibit a high affinity and specificity towards the antigen (analyte) in solution on being immobilized on the biosensor surface.

[@bib3] have presented an immunoassay set-up that uses a small and stable peptide sequence as the immobilized recognition element (receptor) ([@bib10]). [@bib3] indicate that their recognition elements are small helix loop-helix motifs. These recognition elements contain natural binders of the target analyte. Furthermore, these motifs are easily accessible. Also, these authors indicate concerted modifications made for immobilization at the artificial helices do not affect binding properties.

[@bib3] have presented a new sandwich-type assay for the detection of C-reactive protein (CRP). They used a tailored binder as the capture element on the sensor surface, and an antibody as a detection element. C-reactive protein is a protein found in blood. Its levels rise in response to inflammation. [@bib68] indicate that its physiological role is to bind to phosphocholine expressed on the surface of dead or dying cells in order to activate the complement system via the C1Q complex.

CRP is a general marker for inflammation and infection. It can be used as a very rough proxy for heart disease risk. [@bib48] emphasize that since many factors are responsible for CRP level elevations, thus it is not a very specific prognostic indicator. Also the patients with elevated basal levels of CRP are at an increased risk of diabetes ([@bib60]), hypertension and cardiovascular disease.

[Figure 11.10(a)](#f0055){ref-type="fig"} shows the binding and dissociation of 5.45 × 10^−8^ M CRP in solution to the new sandwich assay design that contains a high affinity polypeptide scaffold as the immobilized capture element and an antibody for detection ([@bib3]). As mentioned above a biosensor based on reflectometric interference spectroscopy (RlfS) was used. A dual-fractal analysis is required to describe the binding kinetics. A single-fractal analysis is adequate to describe the dissociation kinetics. The values of (a) the binding rate coefficient k and the fractal dimension, D~f~ for a single-fractal analysis, (b) the binding rate coefficients, k~1~ and k~2~ and the fractal dimensions, D~f1~ and D~f2~ for a dual-fractal analysis, and (c) the dissociation rate coefficient, k~d~ and the fractal dimension, D~fd~ for a single-fractal analysis are given in [Table 11.5a](#t0050){ref-type="table"}, [Table 11.5b](#t0055){ref-type="table"} .Figure 11.10Binding of different concentrations in 10^−8^ M of C-reactive protein (CRP) to a new sandwich assay design using a label-free detection method RIfS (reflectometric interference spectroscopy) ([@bib1]): (a) 5.45 × 10^−8^; (b) 4.36 × 10^−8^; (c) 2.18 × 10^−8^.Table 11.5aBinding and Dissociation Rate Coefficients for Different Concentrations of C-Reactive Protein (CRP) in Solution to a Sandwich-Type Assay Using a Label-free Detection Method, RIfS (Reflectometric Interference Spectroscopy) ([@bib1])Analyte in Solution/Receptor on Surfacekk~1~k~2~k~d~5.48 × 10^−8^ M CRP/fluorescently labeled antibody0.1088 ± 0.02110.04991 ± 0.00501.2621 ± 0.01240.0139 ± 0.000814.36 × 10^−8^ M CRP/fluorescently labeled antibody0.1148 ± 0.02260.04911 ± 0.00501.4889 ± 0.01020.02078 ± 0.000682.18 × 10^−8^ M CRP/fluorescently labeled antibody0.1206 ± 0.02520.04911 ± 0.00501.8137 ± 0.01170.0207 ± 0.0009Table 11.5bFractal Dimensions for the Binding and the Dissociation Phases for Different Concentrations of C-Reactive Protein (CRP) in Solution to a Sandwich Type Assay Using a Label-Free Detection Method, RIfS (Reflectometric Interference Spectroscopy) ([@bib1])Analyte in Solution/Receptor on SurfaceD~f~D~f1~D~f2~D~fd~5.48 × 10^−8^ M CRP/fluorescently labeled antibody1.8950 ± 0.12101.5344 ± 0.01332.723 ± 0.037042.1488 ± 0.084724.36 × 10^−8^ M CRP/fluorescently labeled antibody1.92 ± 0.12881.5344 ± 0.11332.7872 ± 0.0437802.3818 ± 0.04442.18 × 10^−8^ M CRP/fluorescently labeled antibody1.9430 ± 0.11331.5344 ± 0.11332.8601 ± 0.025342.4560 ± 0.05786

It is of interest to note that for a dual-fractal analysis, an increase in the fractal dimension by a factor of 1.78 from a value of D~f1~ equal to 1.5344 to D~f2~ equal to 2.723 leads to an increase in the binding rate coefficient by a factor of 25.29 from a value of k~1~ equal to 0.04991 to k~2~ equal to 1.2621. Once again, an increase in the degree of heterogeneity on the biosensor surface leads to an increase in the binding rate coefficient. In this case, the affinity, K~1~ (=k~1~/k~d~) and K~2~(=k~2~/k~d~) are 3.59 and 90.8, respectively.

[Figure 11.10(b)](#f0055){ref-type="fig"} shows the binding and dissociation of 4.36 × 10^−8^ M CRP in solution to the new sandwich assay design ([@bib3]). A dual-fractal analysis is once again required to describe the binding kinetics. A single-fractal analysis is adequate to describe the dissociation kinetics. The values of (a) the binding rats coefficient k and the fractal dimension, D~f~ for a single-fractal analysis, (b) the binding rate coefficients, k~1~ and k~2~ and the fractal dimensions, D~f1~ and D~f2~ for a dual-fractal analysis, and (c) the dissociation rate coefficient, k~d~ and the fractal dimension, D~fd~ for a single-fractal analysis are given in [Table 11.5a](#t0050){ref-type="table"}, [Table 11.5b](#t0055){ref-type="table"}.

It is of interest to note that for a dual-fractal analysis, an increase in the fractal dimension by a factor of 1.82 from a value of D~f1~ equal to 1.5344 to D~f2~ equal to 2.7872 leads to an increase in the binding rate coefficient by a factor of 30.32 from a value of k~1~ equal to 0.04991 to k~2~ equal to 1.4889. Once again, an increase in the degree of heterogeneity on the biosensor surface leads to an increase in the binding rate coefficient. In this case, the affinity, K~1~(=k~1~/k~d~) and K~2~(=k~2~/k~d~) are 2.40 and 71.6, respectively.

[Figure 11.10(c)](#f0055){ref-type="fig"} shows the binding and dissociation of 2.18 × 10^−8^ M CRP in solution to the new sandwich assay design ([@bib3]). A dual-fractal analysis is once again required to describe the binding kinetics. A single-fractal analysis is adequate to describe the binding kinetics. The values of (a) the binding rate coefficient k and the fractal dimension, D~f~ for a single-fractal analysis, (b) the binding rate coefficients, k~1~ and k~2~ and the fractal dimensions, D~f1~ and D~f2~ for a dual-fractal analysis, and (c) the dissociation rate coefficient, k~d~ and the fractal dimension, D~fd~ for a single-fractal analysis are given in [Table 11.5a](#t0050){ref-type="table"}, [Table 11.5b](#t0055){ref-type="table"}

It is of interest to note that for a dual-fractal analysis, an increase in the fractal dimension by a factor of 1.86 from a value of D~f1~ equal to 1.5344 to D~f2~ equal to 2.8601 leads to an increase in the binding rate coefficient by a factor of 36.93 from a value of k~1~ equal to 0.04991 to k~2~ equal to 1.8137. Once again, an increase in the degree of heterogeneity on the biosensor surface leads to an increase in the binding rate coefficient. In this case, the affinity, K~1~ (=k~1~/k~d~) and K~2~(=k~2~/k~d~) are 2.37 and 87.62, respectively.

[Figure 11.11(a)](#f0060){ref-type="fig"} and [Table 11.5(a)](#t0050){ref-type="table"} show for a dual-fractal analysis the decrease in the binding rate coefficient, k~2~ with an increase in the CRP concentration in solution in the 2.18−5.48 × 10^−8^ M range. For the data shown in Figure 13.11(a) the binding rate coefficient, k~2~ is given by:$$k_{2} = \left( 2.444 \pm 0.148 \right)\left\lbrack {CRP} \right\rbrack^{- 0.368 \pm 0.086}$$ Figure 11.11(a) Decrease in the binding rate coefficient, k~2~, with an increase in the CRP concentration in solution. (b) Increase in the binding rate coefficient, k~2~, with an increase in the fractal dimension, D~f2~. (c) Decrease in the fractal dimension, D~f2~, with an increase in the CRP concentration in solution. (d) Decrease in the dissociation rate coefficient, k~d~, with an increase in the CRP concentration in solution. (e) Increase in the dissociation rate coefficient, k~d~, with an increase in the fractal dimension for dissociation, D~fd~. (f) Decrease in the affinity, K~2~ (=k~2~/k~d~), with an increase in the fractal dimension ratio, D~f2~/D~fd~. (g) Increase in the dissociation rate coefficient, k~d~ with an increase in the fractal dimension, D~fd~. (h) Decrease in the affinity, K~2~ with an increase in D~f2~/D~fd~.

The fit is good. Only three data points are available. The availability of more data points would lead to a more reliable fit. The binding rate coefficient, k~2~ decreases with an increase in the CRP concentration in solution in the 2.18−5.45×10^−8^ M concentration range, and exhibits less than a negative one half (equal to -0.368) order of dependence on the CRP concentration in solution.

[Figure 11.11(b)](#f0060){ref-type="fig"} and [Table 11.5(a)](#t0050){ref-type="table"} show for a dual-fractal analysis the increase in the binding rate coefficient, k~2~ with an increase in the fractal dimension, D~f2~. For the data shown in [Figure 11.11(b)](#f0060){ref-type="fig"} the binding rate coefficient, k~2~ is given by:$$k_{2} = \left( 0.000732 \pm 0.000003 \right)D_{f2}^{7.435 \pm 0.135}$$

The fit is very good. Only three data points are available. The availability of more data points would lead to a more reliable fit. The binding rate coefficient, k~2~ exhibits close to a seven and one-half (equal to 7.435) order of dependence on the fractal dimension, D~f2~ on the biosensor surface. This indicates that the binding fate coefficient, k~2~ is very sensitive to the fractal dimension or the degree of heterogeneity on the biosensor surface.

[Figue 11.11(c)](#f0060){ref-type="fig"} show for a dual-fractal analysis the decrease in the fractal dimension, D~f2~ with an increase in the CRP concentration in solution in the 2.18−5.45 × 10^−8^ M range. For the data shown in [Figure 11.11(c)](#f0060){ref-type="fig"} the fractal dimension, D~f2~ is given by:$$D_{f2} = \left( 2.977 \pm 0.026 \right)\mspace{9mu}\left\lbrack {CRP} \times 10^{- 8} \right\rbrack^{- 0.0494 \pm 0.01289}$$

The fit is good. Only three data points are available. The availability of more data points would lead to a more reliable fit. The fractal dimension, exhibits a very mild dependence on the CRP concentration in the 2.18−5.45×10^−8^ M concentration range.

[Figure 11.11(d)](#f0060){ref-type="fig"} shows the increase in the affinity K~1~ (=k~1~/k~d~) with an increase in the CRP concentration in solution in the 2.18−5.45 × 10^−8^ M range. For the data shown in [Figure 11.11(d)](#f0060){ref-type="fig"}, the affinity, K~1~ is given by:$$K_{1} = \left( k_{1}/k_{d} \right) = \left( 1.724 \pm 0.456 \right)\ \left\lbrack {CRP} \right\rbrack^{0.349 \pm 0.346}$$

The fit is reasonable. Only three data points are available. The availability of more data points would lead to a more reliable fit. The availability of more data points would lead to a more reliable fit. The affinity, K~1~ exhibits only a mild, less than one-half (equal to 0.349) order of dependence on the CRP concentration in solution in the 2.18−5.45 × 10^−8^ M range.

[Figure 11.11(e)](#f0060){ref-type="fig"} shows the increase in the affinity K~2~ (=k~2~/k~d~) with an increase in the CRP concentration in solution in the 2.18−5.45 × 10^−8^ M range. For the data shown in [Figure 11.11(e)](#f0060){ref-type="fig"}, the affinity, K~2~ is given by:$$K_{2} = \left( k_{2}/k_{d} \right) = \left( 58.422 \pm 1.076 \right)\ \left\lbrack {CRP} \right\rbrack^{0.266 \pm 00269}$$

The fit is very good. Only three data points are available. The availability of more data points would lead to a more reliable fit. The availability of more data points would lead to a more reliable fit. The affinity, K~2~ exhibits only a mild, less than one-half (equal to 0.266) order of dependence on the CRP concentration in solution in the 2.18−5.45 × 10^−8^ M range.

[Figure 11.11(f)](#f0060){ref-type="fig"} shows the decrease in the dissociation rate coefficient, k~d~ with an increase in the CRP concentration in solution in the 2.18−5.45 M × 10^−8^ M range. For the data shown in [Figure 11:11(f)](#f0060){ref-type="fig"}, the dissociation rate coefficient k~d~ is given by:$$k_{d} = \left( 0.00290 \pm 0.0083 \right)\mspace{9mu}\left\lbrack {CRP} \right\rbrack^{- 0.367 - 0.378}$$

The fit is poor. There is scatter in the data. This is reflected in the error in the estimated value of the order of dependence of k~d~ on the CRP concentration in solution. Only the negative sign is applicable since the dissociation rate coefficient, k~d~ decreases with an increase in the CRP concentration in solution.

[Figure 11.11(g)](#f0060){ref-type="fig"} and [Table 11.5a](#t0050){ref-type="table"}, [Table 11.5b](#t0055){ref-type="table"} show the increase in the dissociation rate coefficient, k~d~ with an increase in the fractal dimension for dissociation, D~fd~. For the data shown in [Figure 11.11(g)](#f0060){ref-type="fig"}, the dissociation rate coefficient, k~d~ is given by:$$k_{d} = \left( 0.000979 \pm 0.000080 \right)D_{fd}^{3.449 \pm 0.8030}$$

The fit is good. Only three data points are available. The availability of more data points would lead to a more reliable fit. The dissociation rate coefficient, k~d~ exhibits close to a three and one-half (equal to 3.449) order of dependence on the fractal dimension in the dissociation phase, D~fd~. This indicates that the dissociation rate coefficient, k~d~ is very sensitive to the degree of heterogeneity that exists on the biosensor surface in the dissociation phase.

[Figure 11.11(h)](#f0060){ref-type="fig"} shows the decrease in the affinity, K~2~ (=k~2~/k~d~) with an increase in the ratio of the fractal dimensions, (D~f2~/D~fd~). For the data shown in [Figure 11.11(h)](#f0060){ref-type="fig"} the affinity, K~2~ is given by:$$K_{2} = \left( k_{2}/k_{d} \right) = \left( 90.76 \pm 13.61 \right)\mspace{9mu}\left( D_{f2}/D_{fd} \right)^{- 0.890 - 1.038.}$$

The fit is poor. Only three data points are available. The availability of more data points would lead to a more reliable fit. The poor fit is expressed as the error in the power to which the ration of the fractal dimensions is raised. Only the negative power is applicable since the affinity, K~2~ decreases with an increase in the fractal dimension, ratio, D~f2~/D~fd~.

[@bib64] have recently developed an integrated automatic electrochemical Immunosensor array for the detection of five hepatitis virus antigens: hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), and hepatitis E virus (HEV) ([@bib2] **)**. [@bib64] further indicate that hepatitis viruses are one of the leading causes of mortality **(** [@bib13] **)**. Thus, an early diagnosis for hepatitis B viruses is critical. [@bib64] further emphasize that the simultaneous determination of multiple virus antigens is helpful in clinical diagnosis since the patient usually suffers from multiple virus antigens ([@bib19]; [@bib32] **)**.

[@bib64] emphasize that potentiometric assays are high-throughput systems, are label-free, exhibit low assay cost, and their simplicity permits miniaturization as well as signal quantification ([@bib77], [@bib65]). Thus, [@bib64] have developed their electrochemical immunosensor array for the simultaneous determination of five-type hepatitis virus antigens in five minutes.

The binding of 200 ng/ml of HAV to the Immunosensor array ([@bib64]) may be modeled by a dual-fractal analysis. Figure not shown. The values of the binding rate coefficient, k and the fractal dimension, D~f~ for a single-fractal analysis ar 10.252 ± 1.313 and 2.4166 ± 0.2352, respectively. For a dual-fractal analysis, (a) the binding rate coefficients, k~1~ and k~2~ are 10.30 ± 0.818, and 20.493 ± 0.862, respectively, and (b) the fractal dimensions, D~f1~ and D~f2~ are 0.902 ± 0.147, and 2.417± 0.235, respectively.

Note that as the fractal dimension increases by a factor of 2.68 from a value of D~f1~ equal to 0.902 to D~f2~ equal to 2.417, the binding rate coefficient increases by a factor of 1.99 from a value of k~1~ equal to 10.30 to k~2~ equal to 20.493. Once again, an increase in the degree of heterogeneity or the fractal dimension on the immunosensor array surface leads to an increase in the binding rate coefficient.

13.4. Conclusions {#s0050}
=================

A fractal analysis is used to analyze the binding and dissociation (if applicable) kinetics of biomarkers to different biosensor surfaces. Both single- and a dual-fractal analyses are used to analyze the binding and the dissociation kinetics. The dual-fractal analysis is used only if the single-fractal analysis does not provide an adequate fit.

For the binding and dissociation of IFN-gamma in solution to the aptamer modification ([@bib69]), and for a single-fractal analysis, the (1) binding rate coefficient, k, exhibits close to a third (equal to 3.01) order of dependence on the fractal dimension or the degree of heterogeneity that exists on the biosensor surface and (2) the affinity, K (=k/kd), exhibits close to a fifth (equal to 5.064) order of dependence on the ratio of fractal dimensions, D~f~/D~fd~. This indicates that both the binding rate coefficient, k, and the affinity, K, are very sensitive to the nature or the degree of heterogeneity that exists on the biosensor surface.

For the binding of different concentrations of CA-II anhydrase in solution (1) the binding rate coefficient, k, exhibits a mild (equal to 0.435) order of dependence on the CA-II anhydrase concentration in solution, (2) the binding rate coefficient, k, exhibits close to a second (equal to 2.011) order of dependence on the fractal dimension, D~f~, that exists on the biosensor surface, and (3) the ratio of the binding rate coefficients, k~2~/k~1~, exhibits higher than a third (equal to 3.386) order of dependence on the ratio of fractal dimensions, D~f2~/D~f1~.

The relationships presented above are typical of the ones presented for the biomarkers for the other diseases analyzed and presented in this chapter. They provide a means by which these rate coefficients or affinities may be manipulated in desired directions in order to improve the different biosensor performance parameters. The more sensitive a biosensor is for a specific biomarker for a particular disease the earlier it may be detected. Needless to say the early detection of biomarkers for different diseases should lead to a better prognosis. Surely, as expected, there is considerable effort and resources being spent in this direction, and correctly so.

[^1]: LSPCF, localized surface plasmon resonance coupled fluorescence.

[^2]: LSPCF, localized surface plasmon resonance coupled fluorescence.
